PRESS RELEASE

REVEAL GENOMICS® Unveils TNBCDX®: the First Genomic Test Designed for Early-stage Triple-Negative Breast Cancer

NEWS

Genomic assay changes minds on HER2+ BC treatment

BLOG

We continue to gather more support data for HER2DX®

Learn more

PRESS RELEASES

REVEAL GENOMICS® Unveils TNBCDX®: the First Genomic Test Designed for Early-stage Triple-Negative Breast Cancer

REVEAL GENOMICS® Announces Positive Top-Line Results For HER2DX® in CLEOPATRA Phase III Trial

Reveal Genomics® HER2DX® Genomic Test Demonstrates Significant Potential in HER2-Positive Advanced Gastric Cancer

REVEAL GENOMICS® to evaluate prospective real-time performance of HER2DX® genomic test in the United States

REVEAL GENOMICS® HER2DX® Genomic Test to be validated in Pivotal ECOG-ACRIN COMPASSHER2 pCR TRIAL in HER2+ breast cancer

REVEAL GENOMICS® HER2DX® genomic test to undergo first prospective trial as part of the DEFINITIVE project, funded by the European Commission

Our CSO and co-founder, Dr. Aleix Prat has been awarded the National Research Award "Doctores Diz Pintado" for his work

SABCS23: REVEAL GENOMICS® UNLEASHES GROUNDBREAKING DNADX® LIQUID BIOPSY DATA FOR METASTATIC BREAST CANCER

REVEAL GENOMICS® anuncia la inclusión de su test HER2DX® en las guías clinicas SEOM para cáncer de mama HER2+ en estadios iniciales

REVEAL GENOMICS® Announces Positive Top-Line Results FOR HER2DX® in MEDSIR’S PHERGAIN Trial

REVEAL GENOMICS®´ breakthrough technology enters the liquid biopsy field in Oncology

REVEAL GENOMICS presents the latest HER2DX® data in HER2+ breast cancer at SABCS 2022

HER2DX® recognized by TIME as one of the Best Inventions of 2022

REVEAL GENOMICS® announces positive top-line results for HER2DX® in APT and ATEMPT trials

First clinical impact data of HER2DX® according to two independent studies presented at the SEOM congress

Primeros datos de impacto clínico del HER2DX®️ según dos estudios independientes presentados en el Congreso de la SEOM

Strategic partnership between MEDSIR and REVEAL GENOMICS® for cancer research

Alianza estratégica entre MEDSIR y REVEAL GENOMICS® para investigar contra el cáncer

ESMO 2022: REVEAL GENOMICS®️ presents new validation data of HER2DX®️ in the PerELISA trial

Reveal Genomics y HM Hospitales firman un acuerdo para ofrecer el test genómico HER2DX®️ en su portfolio

Reveal Genomics Announces Research Collaboration in HER2+ Breast Cancer

REVEAL GENOMICS® Markets HER2DX®, The World's First Genomic Test for Personalized HER2+ Breast Cancer Treatment

HER2DX: First genomic test for personalized HER2+ breast cancer treatments

REVEAL GENOMICS APPOINTS PATRICIA VILLAGRASA-GONZÁLEZ CHIEF EXECUTIVE OFFICER

SPIN OFF-REVEAL GENOMICS EMERGES TO DEVELOP INNOVATIVE DIAGNOSTICS TESTS IN ONCOLOGY

Genomic assay changes minds on HER2+ BC treatment

REVEAL GENOMICS®´ Breakthrough Technology Enters the Liquid Biopsy Field in Oncology

SABCS23: Reveal Genomics® Unleashes Groundbreaking DNADX® Liquid Biopsy Data for Metastatic Breast Cancer

The Best Inventions of 2022: Personalized Breast Cancer Care Reveal Genomics HER2DX Test

REVEAL GENOMICS, Dana-Farber Using HER2DX to Analyze Data in Three Breast Cancer Trials

REVEAL GENOMICS Introduces HER2DX Breast Cancer Test in Europe, Plans US Expansion

Un test genómico mejora el tratamiento de uno de cada cinco cánceres de mama

Aleix Prat: «As an oncologist, what I want is for these instruments to be available for use in our practices"

REVEAL GENOMICS FICHA EN SOLTI A SU NUEVA CONSEJERA DELEGADA

"MANY MORE ROLE MODELS ARE NEEDED" WOMEN'S PRESENCE IN THE CATALAN BIOMEDICAL ECOSYSTEM

INVESTIGADORES DEL CLINIC Y EL VALL D'HEBRON CREAN LA BIOTECNOLOGICA REVEAL GENOMICS

INVESTIGADORES DEL HOSPITAL CLINIC Y LA VALL D'HEBRON SE UNEN PARA LA DETECCIÓN PRECOZ DEL CÁNCER DE MAMA

SPANISH STARTUP AIMS TO DEVELOP GENOMIC TESTS TO GUIDE BREAST CANCER TREATMENTS

We continue to gather more support data for HER2DX®

Our thoughts about REVEAL GENOMICS creation: A new approach to Physicians and Patients

news

blog